WO1998002197A1 - Revetement thromboresistant de polymere acrylique - Google Patents
Revetement thromboresistant de polymere acrylique Download PDFInfo
- Publication number
- WO1998002197A1 WO1998002197A1 PCT/GB1997/001886 GB9701886W WO9802197A1 WO 1998002197 A1 WO1998002197 A1 WO 1998002197A1 GB 9701886 W GB9701886 W GB 9701886W WO 9802197 A1 WO9802197 A1 WO 9802197A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- parts
- emulsion
- acrylic
- acrylic polymer
- Prior art date
Links
- 229920000058 polyacrylate Polymers 0.000 title claims abstract description 17
- 238000000576 coating method Methods 0.000 title description 8
- 239000011248 coating agent Substances 0.000 title description 7
- 239000000203 mixture Substances 0.000 claims abstract description 60
- 239000000839 emulsion Substances 0.000 claims abstract description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 10
- 229940127219 anticoagulant drug Drugs 0.000 claims abstract description 10
- 229920006243 acrylic copolymer Polymers 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 18
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 11
- 229920001577 copolymer Polymers 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- 239000001993 wax Substances 0.000 claims description 11
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 8
- -1 poly(N-vinyl-2-pyrrolidone) Polymers 0.000 claims description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 230000002209 hydrophobic effect Effects 0.000 claims description 5
- 231100000252 nontoxic Toxicity 0.000 claims description 5
- 230000003000 nontoxic effect Effects 0.000 claims description 5
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 4
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 claims description 4
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 4
- 239000000017 hydrogel Substances 0.000 claims description 4
- 239000012188 paraffin wax Substances 0.000 claims description 4
- 239000001593 sorbitan monooleate Substances 0.000 claims description 4
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 4
- 229940035049 sorbitan monooleate Drugs 0.000 claims description 4
- 239000001589 sorbitan tristearate Substances 0.000 claims description 4
- 235000011078 sorbitan tristearate Nutrition 0.000 claims description 4
- 229960004129 sorbitan tristearate Drugs 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- TUZBYYLVVXPEMA-UHFFFAOYSA-N butyl prop-2-enoate;styrene Chemical group C=CC1=CC=CC=C1.CCCCOC(=O)C=C TUZBYYLVVXPEMA-UHFFFAOYSA-N 0.000 claims description 3
- 238000000151 deposition Methods 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- 229910001220 stainless steel Inorganic materials 0.000 claims description 3
- 239000010935 stainless steel Substances 0.000 claims description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 3
- 229940038773 trisodium citrate Drugs 0.000 claims description 3
- NLELMFKBXZLTNC-UHFFFAOYSA-N 2-ethylhexyl prop-2-enoate;styrene Chemical group C=CC1=CC=CC=C1.CCCCC(CC)COC(=O)C=C NLELMFKBXZLTNC-UHFFFAOYSA-N 0.000 claims description 2
- 102000007625 Hirudins Human genes 0.000 claims description 2
- 108010007267 Hirudins Proteins 0.000 claims description 2
- 125000005396 acrylic acid ester group Chemical group 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000007664 blowing Methods 0.000 claims description 2
- 239000007766 cera flava Substances 0.000 claims description 2
- 229960004106 citric acid Drugs 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 239000002628 heparin derivative Substances 0.000 claims description 2
- 229940006607 hirudin Drugs 0.000 claims description 2
- 239000000416 hydrocolloid Substances 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 229920000515 polycarbonate Polymers 0.000 claims description 2
- 239000004417 polycarbonate Substances 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229940068968 polysorbate 80 Drugs 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 238000004382 potting Methods 0.000 claims description 2
- 238000007711 solidification Methods 0.000 claims description 2
- 230000008023 solidification Effects 0.000 claims description 2
- 239000003039 volatile agent Substances 0.000 claims description 2
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 claims 1
- 238000007598 dipping method Methods 0.000 claims 1
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 238000001035 drying Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000004814 polyurethane Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
- A61L33/0029—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate using an intermediate layer of polymer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/064—Use of macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
Definitions
- the present invention relates to a method of coating a surface to render it thromboresistant.
- Thromboresistance is important for medical devices exposed to blood flow for an extended length of time. Failure to render the surface of such a device thromboresistant can result in formation of a thrombosis, which can lodge in a life threatening position in a patient.
- a number of factors can increase the thromboresistance of a surface, but no one single factor appears to ensure complete thromboresistance.
- Anti-coagulants are well known and can be deposited on a surface to improve its thromboresistance.
- a method of raising the thromboresistance of a surface of a medical device by depositing on it a non-toxic acrylic polymer composition.
- a non-toxic acrylic polymer composition for r sing the thromboresistance of a surface on which it is deposited.
- the composition is deposited by flowing the composition in a water based emulsion of it over the surface.
- the flowing can be achieved by pumping the emulsion through it.
- the medical device is of complex shape, since it enables interstices which the blood can readily reach in use of the device to be treated.
- the medical device can be dipped into the emulsion. The process can be completed by blowing warm air through or over the device. This removes the water .and any residual low molecule weight volatiles, from the emulsion, leaving the acrylic polymer composition deposited on the surface.
- the acrylic polymer is provided as a copolymer.
- better thromboresistance can be provided by incorporation of a water soluble anti-coagul.ant into the emulsion.
- the anti-coagulant is deposited with the acrylic polymer. It acts to discourage initiation of coagulation on the surface.
- the anti-coagatet can be heparin or heparin derivatives, trisodium citrate, citric acid or hirudin or hirudin derivatives.
- a hydrophobic material can be incorporated in the emulsion.
- an emulsifiable wax can be used. It is deposited with the acrylic polymer and by its surface energy discourages any deposit from blood on the surface having the composition on it. Where both anti-coagulant and hydrophobic materials are incorporated, it is believed that the latter slows leaching of the former from the composition.
- Figure 1 is a diagrammatic view of a blood heat exchanger being treated in a first step in depositing an acrylic copolymer composition in accordance with the invention
- Figure 2 is a similar view of a second step in the treatment of the heat exchanger; and Figure 3 is a similar view of other medical devices being treated in accordance with the invention.
- Figure 1 shows a pump 4 connected by pipes 5, 6 to the inlet 2 .and outlet 3 of the heat exchanger via a vat 7 of emulsified thromboresistant composition described below.
- the composition is pumped through it, allowing the emulsified components of the composition to deposit over the entire internal wetted surface of the heat exchanger.
- the pump After a suitable length of time for the composition to build up, typically 20 minutes, the pump is stopped and the pipes 5, 6 removed. After the remaining liquid has drained from it, the exchanger has a drying air duct 11 connected to the inlet 2 and a blower 12 blows air through the exchanger until the composition has dried, see
- FIG. 1 A moisture trap 13 and an exhaust extraction fan 14 are fitted to the outlet of the heat exchanger. After drying, the inlet and outlet are sealed until the device is used.
- the heat exchanger is made of a variety of dissimilar materials.
- the composition of the emulsified thromboresistant composition is as follows (in parts by weight):
- Acrylic copolymer emulsion typically Texicryl TD 6213 100 parts
- Anti-coagulant typically trisodium citrate 0-30 parts
- Figure 3 shows an alternative method of treatment, useful for elongate devices 21, such as stents and catheters. These are suspended from hooks 22 above a vat 23 of emulsified thromboresistant composition. The hooks are ganged together and can be lowered towards the vat, for immersion of the devices in the composition. They are successively lowered and raised until the composition has built on the surface of the devices to a sufficient extent. Where it is critical that all surfaces are completely covered including the point of connection to the hooks - as in a stent as opposed to a catheter or wound drain having a . n end left outside the body - the devices can be upended halfway through the treatment process. As with the heat exchanger, the final step in the treatment is the drying of the composition deposited on the devices. Stents are usually of stainless steel and can be treated with the same composition as the heat exchanger.
- Wound drainage catheters are usually of polyvinylchloride PVC, polyurethane PU, or silicone material. The latter two materials are known to be more thromboresistant. Tests have shown the thromboresistance of PNC catheters can be improved to the level of those of PU catheters by treatment with a similar composition to that used for the heat exchanger, without the wax emulsion.
- the hydrogel coating can be an aqueous solution of poly(hydroxy ethyl methacrylate) (HEMA), polyvinylalcohol (PVOH), poiy( ⁇ -vinyl-2-pyrrolidone) inte ⁇ olymer (PVP) or poly(ethylene oxide) (PEO) as well as suitable hydrocolloids.
- HEMA poly(hydroxy ethyl methacrylate)
- PVOH polyvinylalcohol
- PVP poiy( ⁇ -vinyl-2-pyrrolidone) inte ⁇ olymer
- PEO poly(ethylene oxide)
- Texicryl TD 6213 (a Scott Bader trade name) is a styrene-acrylate copolymer emulsion. It is anticipated that other acrylic compositions will be effective, in particular copolymers based on: (meth)acrylic esters styrene and acrylic acid esters styrene and (meth)acrylic esters.
- Texicryl TD 6213 other suitable polymers include Revacryl 100, 123, 143, 612, all products of Harlow Chemical Co. Ltd., Harlow, England.
- Texicryl TD 6213 is a copolymer emulsion, formed by emulsion polymerisation.
- the copolymer has a styrene butyl acrylate backbone, with a glass transition temperature of -12°C.
- styrene-2-ethyl hexyl acrylate can be used.
- the emulsion stabilising system utilises an alkali soluble copolymer with carboxylic acid functionality. This is used to achieve high resistance to water attack. Ammonia is used to solubilise the copolymer which, on drying, leaves an insoluble ammonium salt.
- the carboxylic acid functionality gives good compatibility (and potentially chemical bonding) with the styrene butyl acrylate, the main polymer, rendering the whole system resistant to re-emulsification.
- acrylic polymers are suitable. In particular they should be non-toxic. For devices having a long life in use they should be resistant to attack by body fluids.
- the wax emulsion is preferably based on either beeswax or paraffin to avoid toxicological problems.
- the composition of a preferred paraffin wax emulsion is as follows (in parts by weight): Paraffin Wax BP
- composition of a preferred beeswax emulsion is as follows (in parts by weight):
- Advantages of the invention can include: i) No unusual cleaning of the medical devices (beyond that dictated by their medical use) prior to treatment in accordance with the invention is thought to be necessary; ii) The compositions and coating processes involved are low cost; iii) Use of devices treated with the coating is anticipated to result in improvements in patient safety, care and recovery rates; iv) Use of an aqueous emulsion avoids the use of solvents which are expensive and/or awkward to dispose of and avoids involvement in VOC regulations.
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Paints Or Removers (AREA)
- Materials For Medical Uses (AREA)
Abstract
La présente invention concerne une composition polymère acrylique permettant d'augmenter la thromborésistance d'une surface sur laquelle elle est déposée et comprenant les ingrédients suivants (en parties en poids): émulsion de copolymère acrylique poids sec 100 parties, anticoagulant 0-60, émulsion de cire poids sec 0-30 parties, eau 100-700 parties.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU36268/97A AU3626897A (en) | 1996-07-13 | 1997-07-11 | Thromboresistant coating made of acrylic polymer |
| GB9900635A GB2330361B (en) | 1996-07-13 | 1997-07-11 | Thromboresistant coating made of acrylic polymer |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9614784.8 | 1996-07-13 | ||
| GBGB9614784.8A GB9614784D0 (en) | 1996-07-13 | 1996-07-13 | Thromboresistant coating |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1998002197A1 true WO1998002197A1 (fr) | 1998-01-22 |
Family
ID=10796895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB1997/001886 WO1998002197A1 (fr) | 1996-07-13 | 1997-07-11 | Revetement thromboresistant de polymere acrylique |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU3626897A (fr) |
| GB (2) | GB9614784D0 (fr) |
| WO (1) | WO1998002197A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0982041A1 (fr) * | 1998-08-21 | 2000-03-01 | Medtronic Ave, Inc. | Revêtement tromborésistant à base de silanes ou de siloxanes |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0003389A1 (fr) * | 1978-01-19 | 1979-08-08 | The British Petroleum Company p.l.c. | Procédé de revêtement de surfaces sous-marines avec de la cire et compositions de revêtement ainsi appliquées |
| EP0323341A2 (fr) * | 1987-12-25 | 1989-07-05 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Instrument médical |
| WO1989007520A1 (fr) * | 1988-02-19 | 1989-08-24 | Bristol-Myers Company | Procede d'enduction de surfaces polymeres et produits enduits realises au moyen dudit procede |
| EP0484057A2 (fr) * | 1990-11-02 | 1992-05-06 | The Dow Chemical Company | Surfaces antithrombogènes, leur préparation et matériau pour leur préparation |
| DE4334272A1 (de) * | 1993-10-07 | 1995-04-13 | Stemberger Axel Dr | Beschichtung für Biomaterial |
-
1996
- 1996-07-13 GB GBGB9614784.8A patent/GB9614784D0/en active Pending
-
1997
- 1997-07-11 WO PCT/GB1997/001886 patent/WO1998002197A1/fr active Application Filing
- 1997-07-11 AU AU36268/97A patent/AU3626897A/en not_active Abandoned
- 1997-07-11 GB GB9900635A patent/GB2330361B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0003389A1 (fr) * | 1978-01-19 | 1979-08-08 | The British Petroleum Company p.l.c. | Procédé de revêtement de surfaces sous-marines avec de la cire et compositions de revêtement ainsi appliquées |
| EP0323341A2 (fr) * | 1987-12-25 | 1989-07-05 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Instrument médical |
| WO1989007520A1 (fr) * | 1988-02-19 | 1989-08-24 | Bristol-Myers Company | Procede d'enduction de surfaces polymeres et produits enduits realises au moyen dudit procede |
| EP0484057A2 (fr) * | 1990-11-02 | 1992-05-06 | The Dow Chemical Company | Surfaces antithrombogènes, leur préparation et matériau pour leur préparation |
| DE4334272A1 (de) * | 1993-10-07 | 1995-04-13 | Stemberger Axel Dr | Beschichtung für Biomaterial |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0982041A1 (fr) * | 1998-08-21 | 2000-03-01 | Medtronic Ave, Inc. | Revêtement tromborésistant à base de silanes ou de siloxanes |
| US6248127B1 (en) | 1998-08-21 | 2001-06-19 | Medtronic Ave, Inc. | Thromboresistant coated medical device |
| US6361819B1 (en) | 1998-08-21 | 2002-03-26 | Medtronic Ave, Inc. | Thromboresistant coating method |
| US6830583B2 (en) | 1998-08-21 | 2004-12-14 | Medtronic Ave, Inc. | Thromboresistant coating composition |
| USRE39438E1 (en) * | 1998-08-21 | 2006-12-19 | Medtronic Vascular, Inc. | Thromboresistant coated medical device |
Also Published As
| Publication number | Publication date |
|---|---|
| AU3626897A (en) | 1998-02-09 |
| GB2330361B (en) | 1999-09-15 |
| GB9614784D0 (en) | 1996-09-04 |
| GB2330361A (en) | 1999-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6495241B2 (ja) | 医療用具の製造方法および医療用具 | |
| DE60013890T2 (de) | Biokompatible medizinische artikel und verfahren zu deren herstellung | |
| US6258371B1 (en) | Method for making biocompatible medical article | |
| JP4185226B2 (ja) | 湿潤時に表面が潤滑性を発現する医療用具およびその製造方法 | |
| EP1104681A1 (fr) | Tube, guide ou cathéter avec enduit hydrophile | |
| JPH02277458A (ja) | 改良された親水性滑性被膜 | |
| AU2015351547B2 (en) | Medical device, and method for producing medical device | |
| JP6600560B2 (ja) | 抗血栓性コーティング材の製造方法 | |
| JP5547095B2 (ja) | 湿潤時に表面が潤滑性を有する医療用具 | |
| JPH02503889A (ja) | ポリマー表面のコーティング方法およびその方法を用いてコーティングした製品 | |
| WO2013027556A1 (fr) | Matériau antithrombogène et dispositif médical | |
| JP3522839B2 (ja) | 湿潤時に表面が潤滑性を有する医療用具及びその製造方法 | |
| EP2100627B1 (fr) | Copolymère de (méth)acrylate, procédé de production de celui-ci et dispositif médical | |
| WO1998002197A1 (fr) | Revetement thromboresistant de polymere acrylique | |
| Mardis | Evaluation of Polymeric Materials for Endourologic Devices-Emerging Importance of Hydrogels | |
| US20230119743A1 (en) | Hydrophilic Medical Catheters | |
| JP4626005B2 (ja) | 血液適合性組成物およびそれを被覆した医療用具 | |
| JP2745558B2 (ja) | 易滑性医療用材料 | |
| JPH0819599A (ja) | 湿潤時に表面が潤滑性を有する医療用具及びその製造方法 | |
| JPH02144070A (ja) | 易滑性医療材料 | |
| WO2024181302A1 (fr) | Procédé de production d'un dispositif médical | |
| WO2014123077A1 (fr) | Matériau de revêtement médical et dispositif médical | |
| JP6812191B2 (ja) | 高分子化合物、抗血栓性高分子材料、およびそれを用いた医療機器 | |
| JPS6397158A (ja) | 人工血管 | |
| JPS62258670A (ja) | 人工血管及びその製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA GB JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998505737 Format of ref document f/p: F |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |